CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts

Although carbohydrate antigen 19.9 (CA19.9) is widely used in pancreatic adenocarcinoma (PA), no consensual cut-off value of CA19.9 decrease has been established for treatment monitoring. This was a retrospective study including patients with a baseline CA19.9 ≥ 37 UI/ml and with locally advanced or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	HPB (Oxford, England) England), 2019-05, Vol.21 (5), p.582-588
Hauptverfasser:	Laurent, Lucie, Sefrioui, David, Bignon, Anne-Laure, Parzy, Aurélie, Sidali, Sabrina, Hassine, Mélanie, Gangloff, Alice, Galais, Marie-Pierre, Bouhier-Leporrier, Karine, Michel, Pierre, Di Fiore, Frédéric
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - metabolism Adenocarcinoma - pathology Adult Aged Aged, 80 and over Bilirubin - metabolism Biomarkers, Tumor - metabolism CA-19-9 Antigen - metabolism Disease Progression Female France Humans Life Sciences Male Middle Aged Pancreatic Neoplasms Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Retrospective Studies Sensitivity and Specificity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!